The current epidemic of primary aldosteronism: Causes and consequences

Journal of Hypertension

Volumn 22, Issue 5, 2004, Pages 863-869

  Kaplan, Norman M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aldosterone to renin ratio; Primary aldosteronism; Screening tests

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADENOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; CLINICAL FEATURE; DISEASE ASSOCIATION; DIURETIC THERAPY; EPIDEMIC; ESSENTIAL HYPERTENSION; GENE MUTATION; HUMAN; HYPOKALEMIA; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 2542432149     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200405000-00001     Document Type: Review

References (59)

1. Conn JW. Presidential address II. Primary aldosteronism: new clinical syndrome. J Lab Clin Med 1955; 45:6-17.
2. Kaplan NM. Primary aldosteronism. In: Kaplan's clinical hypertension, 8th edn. Philadelphia: Lippincott Williams & Wilkins; 2002, pp. 455-479.
3. Gordon RD, Klemm SA, Stowasser M, Tunny TJ, Storie WJ, Rutherford JC. How common is primary aldosteronism? Is it the most frequent cause of curable hypertension? Curr Sci 1993; 11 (suppl 5):S310-S311.
4. Anwar YA, White WB, Mansoor GA, Tendler BE. Hyperaldosteronism is a common cause of secondary hypertension missed by primary care physicians and associated with normokalemia. Am J Hypertens 1998; 11:199A.
5. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353:40.
6. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14:311-315.
7. Nishikawa T, Omura T. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54(suppl 1):83-85.
8. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854-2859.
9. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000; 90:394-400.
10. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000; 85:1863-1867.
11. Douma S, Petidis K, Vogiatzis K, Zamboulis C. The aldosterone/PRA ratio (ARR) application in the diagnosis of primary aldosteronism. J Hypertens 2001; 19(suppl 2):S12.
12. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15:896-902.
13. Hood S, Cannon J, Scanlon M, Brown MJ. Prevalence of primary hyperaldosteronism measured by aldosterone to renin ratio and spironolactone testing: Pharst study. J Hypertens 2002; 20 (suppl 4):S119.
14. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.
15. Bernini G, Moretti A, Argenio G, Salvetti A. Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endorcrinol 2002; 146:523-529.
16. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896.
17. Calhoun DA, Nishizaka MK, Zaman MA. High prevalence of obstructive sleep apnea among hypertensive patients with primary hyperaldosteronism. Am J Hypertens 2003; 16:163A.
18. Girerd X, Villeveuve F, Lemaire A, Roux O, Hanon O, Mourad JJ. A clinical prediction rule for primary aldosteronism in drug-resistant hypertensive patients referred to an hypertension clinic. J Hypertens 2003; 21 (suppl 4):S145.
19. Fogari R, Preti P, Mugellini A, Rinaldi A, Pasotti C, Fogari E, Corradi L. Prevalence of primary aldosteronism among hypertensive patients. J Hypertens 2003; 21 (suppl 4):S142.
20. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17:349-352.
21. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21:2149-2157.
22. Davis WW, Newsome HH Jr, Wright LD Jr, Hammond WG, Easton J, Bartter FC. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity. Am J Med 1967; 42:642-647.
23. Ferriss JB, Brown JJ, Fraser R, Kay AW, Neville AM, O'Muircheartaigh IG, et al. Hypertension with aldosterone excess and low plasma-renin: preoperative distinction between patients with and without adrenocortical tumour. Lancet 1970; 2:995-1000.
24. McAreavey D, Murray GD, Lever AF, Robertson JIS. Similarity of idiopathic aldosteronism and essential hypertension. Hypertension 1983; 5:116-121.
25. Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism including surgically correctable forms in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050
26. Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust NZ J Med 1976; 6:131-135.
27. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med 1981; 141:1589-1593.
28. Fiquet-Kempf B, Launay-Mignot P, Bobrie G, Plouin P-F. Is primary aldosteronism underdiagnosed in clinical practice? Clin Exp Pharmacol Physiol 2001; 28:1083-1086.
29. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42:161-165.
30. Chudek J, Witkowicz J, Zarzecki M, Kokot F, Wiecek A. Diagnostic value of plasma aldosterone to renin ratio in hypertensive patients. J Hypertens 2003; 21 (suppl 4):S286.
31. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to- plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31:619-632.
32. Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86:4292-4298.
33. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002; 48:1919-1923.
34. Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76:877-882.
35. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88:2489-2494.
36. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699-705.
37. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002; 57:457-465.
38. Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004; 22:251-255.
39. Nicod J, Bruhin D, Auer L, Vogt B, Frey FJ, Ferrari P. A biallelic gene polymorphism of CYP11β2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J Clin Endocrinol Metab 2003; 88:2495-2500.
40. Connell JMC, Fraser R, MacKenzie S, Davies E. Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? Hypertension 2003; 41:993-999.
41. Inglis GC, Plouin PF, Friel EC, Davies E, Fraser R, Connell JM. Polymorphic differences from normal in the aldosterone synthase gene (CYP11β2) in patients with primary hyperaldosteronism and adrenal tumour (Conn's syndrome). Clin Endocrinol 2001; 54:725-730.
42. Dobrucki T, Ciechanowicz A, Prejbisz A, Postula M, Peczkowska M, Adler G, et al. T(-344)C polymorphism of aldosterone synthase (CYP11β2) gene in Polish patients with primary aldosteronism. J Hypertens 2003; 21 (suppl 4):S317.
43. Davies E, Kenyon CJ. CYP11β2 polymorphisms and cardiovascular risk factors. J Hypertens 2003; 21:1249-1253.
44. Tracy RE, White S. A method of quantifying adrenocortical nodular hyperplasia at autopsy: some use of the method in illuminating hypertension and atherosclerosis. Ann Diagn Pathol 2002; 6:20-29.
45. Guthrie GP Jr, Genest J, Nowaczynski W, Boucher R, Kuchel O. Dissociation of plasma renin activity and aldosterone in essential hypertension. J Clin Endocrinol Metab 1976; 43:446-448.
46. McAlister FA, Lewanczuk RZ. Primary hyperaldosteronism and adrenal incidentaloma: an argument for physiologic testing before adrenalectomy. Can J Surg 1998; 41:299-305.
47. Harper R, Ferrett CG, McKnight JA, McIlrath EM, Russell CF, Sheridan B, Atkinson AB. Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas. Q J Med 1999; 92:643-650.
48. Glodny B, Kühle C, Cromme S, Brockmann J, Winde G. An assessment of diagnostic procedures preparatory to retroperitoneoscopic removal of adenoma in cases of primary hyperaldosteronism. Endocrine J 2000; 47:657-665.
49. Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85:4526-4533.
50. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86:1083-1090.
51. Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, Findling JW. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001; 86:1066-1071.
52. Espiner EA, Ross DG, Yandle TG, Richards AM, Hunt PJ. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 2003; 88:3637-3644.
53. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19:353-361.
54. Weinberger M, White W, Weiss RJ, Carr A, Gatlin M, Bittman R, Krause S. Blood pressure response of eplerenone according to baseline characteristics. Am J Hypertens 2003; 16:218A.
55. Nichizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
56. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002; 359:881-884.
57. Connell JMC. Is there an epidemic of primary aldosterone? J Hum Hypertens 2002; 16:151-152.
58. Padfield PL. Primary aldosteronism, a common entity? The myth persists. J Hum Hypertens 2002; 16:159-162.
59. Kaplan NM. Cautions about the current epidemic of primary aldosteronism. Lancet 2001; 357:953-954.